INDEMNIFICATION AGREEMENTIndemnification Agreement • August 27th, 2004 • Corus Pharma Inc • Delaware
This Indemnification Agreement (this “Agreement”) is made as of , 200 , by and between Corus Pharma, Inc., a Delaware corporation (the “Company”), and (“Indemnitee”).
CORUS PHARMA, INC. AMENDED AND RESTATED INFORMATION AND REGISTRATION RIGHTS AGREEMENTInformation and Registration Rights Agreement • August 27th, 2004 • Corus Pharma Inc • Delaware
THIS AMENDED AND RESTATED INFORMATION AND REGISTRATION RIGHTS AGREEMENT (this “Agreement”) is made as of April 9, 2004, by and among Corus Pharma, Inc., a Delaware corporation (the “Company”), and the undersigned holders of shares of the Company’s Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock listed on the attached Exhibit A, as it may be amended from time to time pursuant to the terms hereof (collectively, the “Investors”).
THIRD AMENDMENT TO OFFICE LEASEOffice Lease • August 27th, 2004 • Corus Pharma Inc
This THIRD AMENDMENT TO OFFICE LEASE (“Third Amendment”) is made as of July 7, 2003, by and between CONNECTICUT GENERAL LIFE INSURANCE COMPANY, a Connecticut corporation, on behalf of its Separate Account R (“Landlord”), and CORUS PHARMA, INC., a Delaware corporation (“Tenant”). Landlord and Tenant hereinafter may be referred to each as a “Party” and collectively as the “Parties.”
FIRST AMENDMENT TO OFFICE LEASEOffice Lease • August 27th, 2004 • Corus Pharma Inc
This First Amendment to Office Lease (this “First Amendment”), is made effective the 6th day of Feb. 2002, by and between Connecticut General Life Insurance Company (“Landlord”) and Corus Pharma, Inc. (“Tenant”).
EMPLOYEE CONFIDENTIALITY, INVENTIONS, AND NON-COMPETITION AGREEMENTNon-Competition • August 27th, 2004 • Corus Pharma Inc • Washington
This Agreement is made and entered into as of May , 2001, by and between Corus Pharma, Inc., a Delaware corporation (“Company”) and A. Bruce Montgomery, M.D. (“Employee”).
AMENDMENT TO SUBLEASESublease • August 27th, 2004 • Corus Pharma Inc • Washington
THIS AMENDMENT TO SUBLEASE (“Amendment”), dated December 19, 2002 (the “Effective Date”) is entered into by and between DENDREON CORPORATION, a Delaware corporation (“Dendreon”), and CORUS PHARMA, Inc., a Delaware corporation (“Subtenant”).
FOURTH AMENDMENT TO OFFICE LEASEOffice Lease • August 27th, 2004 • Corus Pharma Inc
This FOURTH AMENDMENT TO OFFICE LEASE (“Fourth Amendment”) is made as of June 4 , 2004, by and between CONNECTICUT GENERAL LIFE INSURANCE COMPANY, a Connecticut corporation, on behalf of its Separate Account R (“Landlord”), and CORUS PHARMA, INC., a Delaware corporation (“Tenant”). Landlord and Tenant hereinafter may be referred to each as a “Party” and collectively as the “Parties.”
SECOND AMENDMENT TO SUBLEASECorus Pharma Inc • August 27th, 2004 • Washington
THIS SECOND AMENDMENT TO SUBLEASE (“Amendment”), dated July 6, 2003 (the “Effective Date”) is entered into by and between DENDREON CORPORATION, a Delaware corporation (“Dendreon”) and CORUS PHARMA, Inc., a Delaware corporation (“Subtenant”).
SUBLEASESublease • August 27th, 2004 • Corus Pharma Inc
THIS SUBLEASE (“Sublease”), dated September 6, 2002, for reference purposes only, is entered into by and between DENDREON CORPORATION, a Delaware corporation (“Dendreon”) and CORUS PHARMA, a Delaware corporation (“Subtenant”).
Letterhead of Dendreon Corporation]Corus Pharma Inc • August 27th, 2004
SECOND AMENDMENT TO OFFICE LEASEOffice Lease • August 27th, 2004 • Corus Pharma Inc
This SECOND AMENDMENT TO OFFICE LEASE (“Second Amendment”) is made as of Sept. 23rd, 2002, by and between CONNECTICUT GENERAL LIFE INSURANCE COMPANY, a Connecticut corporation, on behalf of its Separate Account R (“Landlord”), and CORUS PHARMA, INC., a Delaware corporation (“Tenant”). Landlord and Tenant hereinafter may be referred to each as a “Party” and collectively as the “Parties.”
CHANGE IN CONTROL SEVERANCE AGREEMENTChange in Control Severance Agreement • August 27th, 2004 • Corus Pharma Inc • Washington
THIS CHANGE IN CONTROL SEVERANCE AGREEMENT (the “Agreement”) is entered into as of , 2004 (the “Effective Date”), by and between (the “Executive”) and Corus Pharma, Inc., a Delaware corporation (the “Company”).
